Status:

UNKNOWN

A Prospective Evaluation of Health Services Outcomes and Emerging Cardiovascular Disease Biomarkers

Lead Sponsor:

Preventive Medicine Research Institute

Conditions:

Coronary Heart Disease

Biomarkers of Cardiovascular Disease

Eligibility:

All Genders

21+ years

Phase:

NA

Brief Summary

The primary aim of the proposed research is to examine the relationship of lifestyle changes to new dietary, biomedical, and cellular parameters among new enrollees entering the "Dr. Dean Ornish Progr...

Eligibility Criteria

Inclusion

  • Eligible patients included those who had a diagnosis of coronary heart disease (CHD) from their physician or health plan, a diagnosis of diabetes, or at least 3 additional cardiac risk factors.
  • A diagnosis of CHD included:
  • having diagnosed CHD based on non-invasive testing such as exercise testing, nuclear imaging, echocardiogram or other test that clearly demonstrates ischemia
  • cardiac catheterization demonstrating CHD
  • eligibility for bypass surgery/PTCA and seeking a clinical alternative
  • coronary bypass surgery
  • PTCA/stent
  • myocardial infarction.
  • Type I or Type II diabetics were eligible for the program.
  • For a participant to be included as a high-risk factor participant, the participant must have either a family history of premature CHD (1st-degree relative (male\<55; female \<65) with MI or sudden cardiac death) or be a male aged \> 45 or a female aged \> 55.
  • In addition, there must be at least two additional cardiovascular risk factors, including:
  • current cigarette smoking (within the past 5 years)
  • hypertension: BP \> 140/90 mm Hg or on antihypertensive medication,
  • low HDL-C: \<35 mg/dl or on medications for lipid therapy
  • elevated apolipoprotein(a): \>30 mg/dl or on medications for elevated lipids
  • high total cholesterol: \> 240 or on medications for elevated lipids
  • high LDL-C: \>160 or on medications for elevated lipids
  • high sensitivity C-Reactive Protein: \> 3 mg/dl and \< 10 mg/dl
  • obesity: BMI \> 30
  • Insulin Resistant State (Metabolic Syndrome X

Exclusion

  • Exclusion criteria included:
  • ischemic left main CHD, with an obstruction greater than 50%
  • significant (\>70%) proximal left anterior descending artery disease and proximal left circumflex artery disease and an ejection fraction less than 50%, \*unstable angina
  • hypotensive response to exercise (\> 20mm Hg drop in systolic BP)
  • history of exercise induced ventricular tachycardia or 3rd degree heart block without evidence of current stability
  • CABG surgery within 4 weeks, unless approved by medical director
  • MI within one month, unless approved by medical director\\
  • HF, with functional limitation and unresponsive to medications
  • current tobacco user not concurrently enrolled in a smoking cessation program with 2-month history of smoking cessation
  • uncontrolled malignant ventricular arrhythmia despite medications and/or implantable cardiac defibrillator (ICD), unless approved by medical director, resides beyond a one-hour commute to the Program site, unless approved by Team, \*history of substance abuse disorder (inc. ETOH) without documentation of a minimum one year of abstinence
  • history of a significant psychiatric disorder without documentation of minimum one-year stability
  • impaired cognitive function, such as dementia or delirium
  • English language literacy unless Program site can accommodate
  • non-ambulatory
  • uncooperative spouse or life partner, defined as obstructive in attitude or behavior
  • the patient is deemed to be potentially disruptive to group setting by the screening team.

Key Trial Info

Start Date :

October 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2009

Estimated Enrollment :

131 Patients enrolled

Trial Details

Trial ID

NCT00820313

Start Date

October 1 2006

End Date

May 1 2009

Last Update

January 12 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Preventive Medicine Research Institute

Sausalito, California, United States, 94965